This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

4OD Stock Overview

A pharmaceutical company, develops therapeutics for the treatment of cancer. More details

4OD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Does not have a meaningful market cap (€44M)

Latest financial reports are more than 6 months old

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Odonate Therapeutics, Inc. Competitors

Biofrontera

XTRA:B8FK

€16.1m

Apontis Pharma

XTRA:APPH

€93.7m

SynBiotic

DUSE:SBX

€20.5m

MPH Health Care

DB:93M1

€110.0m

Price History & Performance

Summary of share price highs, lows and changes for Odonate Therapeutics
Historical stock prices
Current Share Price	US$1.28
52 Week High	US$1.46
52 Week Low	US$1.08
Beta	0.062
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	-95.71%
5 Year Change	n/a
Change since IPO	-93.58%

Recent updates

Shareholder Returns

	4OD	DE Pharmaceuticals	DE Market
7D	0%	-4.1%	1.2%
1Y	n/a	-27.8%	14.0%

Return vs Industry: Insufficient data to determine how 4OD performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 4OD performed against the German Market.

Price Volatility

Is 4OD's price volatile compared to industry and market?
4OD volatility
4OD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 4OD has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 4OD's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	145	Kevin Tang	www.odonate.com

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

Odonate Therapeutics, Inc. Fundamentals Summary

How do Odonate Therapeutics's earnings and revenue compare to its market cap?
4OD fundamental statistics
Market cap	€43.79m
Earnings (TTM)	-€101.27m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is 4OD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4OD income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$102.07m
Earnings	-US$102.07m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-3.47
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 4OD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/08 16:17
End of Day Share Price	2022/08/11 00:00
Earnings	2021/09/30
Annual Earnings	2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Odonate, Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dana Flanders	Goldman Sachs
Michael Yee	Jefferies LLC
Eric Schmidt	TD Cowen

Odonate Therapeutics MUN:4OD Stock Report